Mutant TP53 occurred in the cancers of 2 of 27 evaluable patients (7.4%) in cohort A and 9 of 10 evaluable patients (90%) in cohort B. The remaining patients did not have genomic sequencing performed. This evidence concerns the gene TP53 and cancer.